A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

Also called NCT05018650

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
Route 92 Medical, Inc. (from the registry)
Registry
  • NCT NCT05018650
Other papers using this trial's data
  • SUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy Stroke, 2025-08 DOI, PubMed 40395106

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05018650. Randomized; no masking; primary purpose treatment. Start 2021-12-21 (actual); primary completion 2024-02-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
Condition
Acute Ischemic Stroke
Intervention (Device)
Route 92 Medical Reperfusion System
Lead sponsor
Route 92 Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05018650
Content hash
0b7c169d73b44f42f9c80184cb3bbb1ecc68f189ee4f15af92bb4a86c3908dee